Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension
NCT ID: NCT00267176
Last Updated: 2017-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1020 participants
INTERVENTIONAL
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension
NCT00419796
6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis
NCT00170872
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
NCT00367315
Efficacy and Safety of Lumiracoxib
NCT00267215
Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).
NCT00366938
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lumiracoxib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High blood pressure (\<140/ 90 mmHg) which is controlled by antihypertensive medication(s).
Exclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bradkey Sakran, MD
Role: PRINCIPAL_INVESTIGATOR
Southern Illinois Clinical Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southern Illinois Clinical Research
O'Fallon, Illinois, United States
Novartis
Nuremberg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
MacDonald TM, Reginster JY, Littlejohn TW, Richard D, Lheritier K, Krammer G, Rebuli R. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J Hypertens. 2008 Aug;26(8):1695-702. doi: 10.1097/HJH.0b013e328302c9fe.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCOX189A2428
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.